Increased donor risk: Who should bear the burden?

Liver Transplantation

Volumn 15, Issue 6, 2009, Pages 570-573

  Feng, Sandy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADAVER DONOR; DISEASE SEVERITY; DISEASE TRANSMISSION; EDITORIAL; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MORTALITY; ORGAN DONOR; PRIORITY JOURNAL; RISK FACTOR; STEATOSIS; SURVIVAL RATE;

GRAFT REJECTION; HEPATITIS C; HUMANS; LIVER; LIVER DISEASES; LIVER FAILURE; LIVER TRANSPLANTATION; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TISSUE DONORS;

EID: 68349139314     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21790     Document Type: Editorial

References (43)

1. New York State Department of Health Workgroup. Workgroup on expanded criteria organs for liver transplantation. Liver Transpl 2005;11:1184-1192.
2. Briceno J, Solorzano G, Pera C. A proposal for scoring marginal liver grafts. Transpl Int 2000;13(suppl 1):S249-S252.
3. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9:651-663.
4. Cameron AM, Ghobrial RM, Yersiz H, Farmer DG, Lipshutz GS, Gordon SA, et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006;243:748-753; discussion 53-55.
5. Durand F, Renz JF, Alkofer B, Burra P, Clavien PA, Porte RJ, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 2008;14:1694-1707.
6. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
7. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008;8(pt 2):958-976.
8. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008;8:419-425.
9. Volk ML, Lok AS, Pelletier SJ, Ubel PA, Hayward RA. Impact of the Model for End-Stage Liver Disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology 2008;135:1568-1574.
10. Maluf DG, Edwards EB, Kauffman HM. Utilization of extended donor criteria liver allograft: is the elevated risk of failure independent of the Model for End-Stage Liver Disease score of the recipient? Transplantation 2006;82: 1653-1657.
11. Silberhumer GR, Pokorny H, Hetz H, Herkner H, Rasoul-Rockenschaub S, Soliman T, et al. Combination of extended donor criteria and changes in the Model for End-Stage Liver Disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation 2007;83:588-592.
12. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991;23(pt 2):1538-1540.
13. Briceno J, Padillo J, Rufian S, Solorzano G, Pera C. Assignment of steatotic livers by the Mayo Model for End-Stage Liver Disease. Transpl Int 2005;18:577-583.
14. Amin MG, Wolf MP, TenBrook JA Jr, Freeman RB Jr, Cheng SJ, Pratt DS, et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis. Liver Transpl 2004;10:1468-1475.
15. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
16. Shiffman ML, Saab S, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, et al. Liver and intestine transplantation in the United States, 1995-2004. Am J Transplant 2006;6(pt 2):1170-1187.
17. Maluf D, Edwards E, Stravitz R, Kauffman H. Impact of the donor risk index in the outcomes of HCV+ liver transplant recipients. Liver Transpl 2009;15:592-599.
18. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
19. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
20. Russo MW, Galanko JA, Zacks SL, Beavers KL, Fried MW, Shrestha R. Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C. Am J Transplant 2004;4:1133-1138.
21. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
22. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005;5:549-557.
23. Humar A, Horn K, Kalis A, Glessing B, Payne WD, Lake J. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant 2005;5:399-405.
24. Lawal A, Ghobrial R, Te H, Artinian L, Eastwood D, Schiano TD. Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation. Transplant Proc 2007; 39:3261-3265.
25. Berenguer M. Live donor liver transplantation for hepatitis C: new data, old story. Liver Transpl 2006;12:516-519.
26. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707.
27. Guo L, Orrego M, Rodriguez-Luna H, Balan V, Byrne T, Chopra K, et al. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006;12:560-565.
28. Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, et al. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci 2004; 49:38-41.
29. Shiffman ML, Stravitz RT, Contos MJ, Mills AS, Sterling RK, Luketic VA, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004;10: 1248-1255.
30. Schmeding M, Neumann UP, Puhl G, Bahra M, Neuhaus R, Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 2007;13:687-692.
31. Velidedeoglu E, Mange KC, Frank A, Abt P, Desai NM, Markmann JW, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV- recipients. Transplantation 2004;77:1834-1842.
32. Yagci G, Fernandez LA, Knechtle SJ, D'Alessandro AM, Chin LT, Musat AI, et al. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc 2008;40:219-223.
33. Nguyen JH, Bonatti H, Dickson RC, Hewitt WR, Grewal HP, Willingham DL, et al. Long-term outcomes of donation after cardiac death liver allografts from a single center. Clin Transplant 2009;23:168-173.
34. Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009;15:619-628.
35. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009;29(suppl 2):26-37.
36. Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009;29(suppl 2):3-12.
37. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007;13:975-983.
38. Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, et al. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007;27:758-763.
39. Briceno J, Ciria R, Pleguezuelo M, de la Mata M, Muntane J, Naranjo A, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15:37-48.
40. Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, et al. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 2004;10:599-606.
41. Salizzoni M, Franchello A, Zamboni F, Ricchiuti A, Cocchis D, Fop F, et al. Marginal grafts: finding the correct treatment for fatty livers. Transpl Int 2003;16:486-493.
42. Yilmaz N, Shiffman ML. Impact of the donor liver with steatosis in patients with hepatitis C virus: not so FAst. Liver Transpl 2009;15:4-6.
43. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007;246:940-946; discussion 6-8.